<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">475819101</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180406123817.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">170329e20000501xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/s002280050733</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/s002280050733</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Modulation of midazolam 1-hydroxylation activity in vitro by neurotransmitters and precursors</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[C. Martínez, G. Gervasini, J. A. G. Agúndez, J. A. Carrillo, S. I. Ramos, F. J. García-Gamito, L. Gallardo, J. Benítez]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Objective: The aim of this study was to find whether endogenous substances could modulate CYP3A activity. There is evidence that CYP3A, a major phase-I xenobiotic metabolizing enzyme, is present in human brain but, at the present time, endogenous substrates for such an enzyme remain to be identified. A possible linkage between the CYP2D6 enzyme and serotonergic transmission has been recently reported by our group. In the same manner, structurally related enzymes such as CYP3A could also be related to endogenous compounds. Methods: CYP3A activity was measured using the enzyme-specific substrate midazolam in human liver microsomes. Several neurotransmitters, precursors, and their metabolites, corresponding to three different metabolic routes, were assayed as putative modulators of CYP3A enzyme activity. These comprised serotonergic, catecolaminergic, and GABAergic transmitters and precursors. The inhibitory capacity of ketoconazole, a competitive inhibitor of CYP3A, was also analyzed for comparison. Results: The kinetic analysis of the midazolam 1-hydroxylase activity measured in microsomes from five human liver samples indicated K m values (mean ± SD) of 5.8 ± 4.9 μM, and Vmax values of 1.7 ± 1.4 nmol min−1 per mg microsomal protein in all the samples used in the study. Of the 14 substances analyzed, adrenaline, serotonin, and 5-hydroxytriptofol were full inhibitors of CYP3A enzyme activity (Ki values of 42.3, 26.4, and 43 μM, respectively). The remaining substances were weak inhibitors or had no inhibitory effect. Conclusion: Brain CYP3A activity could be modulated by some neurotransmitters and precursors.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Springer-Verlag Berlin Heidelberg, 2000</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Key words CYP3A</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Metabolism</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Indoleamines</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Martínez</subfield>
   <subfield code="D">C.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Gervasini</subfield>
   <subfield code="D">G.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Agúndez</subfield>
   <subfield code="D">J. A. G.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Carrillo</subfield>
   <subfield code="D">J. A.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Ramos</subfield>
   <subfield code="D">S. I.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">García-Gamito</subfield>
   <subfield code="D">F. J.</subfield>
   <subfield code="u">Service of General Surgery, INSALUD Hospital Merida, Badajoz, Spain, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Gallardo</subfield>
   <subfield code="D">L.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Benítez</subfield>
   <subfield code="D">J.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/s002280050733</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/s002280050733</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Martínez</subfield>
   <subfield code="D">C.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Gervasini</subfield>
   <subfield code="D">G.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Agúndez</subfield>
   <subfield code="D">J. A. G.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Carrillo</subfield>
   <subfield code="D">J. A.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Ramos</subfield>
   <subfield code="D">S. I.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">García-Gamito</subfield>
   <subfield code="D">F. J.</subfield>
   <subfield code="u">Service of General Surgery, INSALUD Hospital Merida, Badajoz, Spain, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Gallardo</subfield>
   <subfield code="D">L.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Benítez</subfield>
   <subfield code="D">J.</subfield>
   <subfield code="u">Department of Pharmacology, Medical School, University of Extremadura, Avda. de Elvas s/n, E-06071 Badajoz, Spain e-mail: jbenitez@unex.es Tel.: +34-924-289458; Fax +34-924-271100, ES</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
